Summary What is already known about this topic?A considerable percentage of the population has received both primary and booster vaccinations,which could potentially provide protection against severe acute respiratory...Summary What is already known about this topic?A considerable percentage of the population has received both primary and booster vaccinations,which could potentially provide protection against severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)Omicron infections and related symptoms.What is added by this report?The self-reported infection rate,as determined from an online survey,reached its peak(15.5%)between December 19 and 21,2022,with an estimated 82.4%of individuals in China being infected as of February 7,2023.During the epidemic,the effectiveness of booster vaccinations against SARS-CoV-2 Omicron infection was found to be 49.0%within three months of vaccination and 37.9%between 3 and 6 months following vaccination.Furthermore,the vaccine effectiveness of the booster vaccination in relation to symptom prevention varied from 48.7%to 83.2%within three months and from 25.9%to 69.0%between 3 and 6 months post-booster vaccination.展开更多
基金This study was supported by the National Key Research and Development Program of China(2021YFC2301604)the Young Elite Scientists Sponsorship Program by CAST(2022QNRC001)+1 种基金Emergency Grants for Prevention and Control of SARS-CoV-2 in Guangdong Province(2022A1111090004)the Science and Technology Program of Guangzhou(202102021285).
文摘Summary What is already known about this topic?A considerable percentage of the population has received both primary and booster vaccinations,which could potentially provide protection against severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)Omicron infections and related symptoms.What is added by this report?The self-reported infection rate,as determined from an online survey,reached its peak(15.5%)between December 19 and 21,2022,with an estimated 82.4%of individuals in China being infected as of February 7,2023.During the epidemic,the effectiveness of booster vaccinations against SARS-CoV-2 Omicron infection was found to be 49.0%within three months of vaccination and 37.9%between 3 and 6 months following vaccination.Furthermore,the vaccine effectiveness of the booster vaccination in relation to symptom prevention varied from 48.7%to 83.2%within three months and from 25.9%to 69.0%between 3 and 6 months post-booster vaccination.
